{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:21:42Z","timestamp":1785464502372,"version":"3.56.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>GV1001, a peptide drug derived from human telomerase reverse transcriptase, has showed the therapeutic effect in the animal model of Alzheimer\u2019s disease (AD), a representative chronic neurodegenerative disease having impaired learning and memory. In our previous studies, GV1001 has showed the multi-functions including anti-apoptosis, anti-oxidative stress, and anti-neuroinflammation in AD-related in vitro and in vivo systems. Here, in addition to these previously reported functions, GV1001 was discovered to reduce the protein level of 4R tau isoform in the pathological condition. There is no studies providing the potential of GV1001 as a therapeutic drug for neurodegenerative movement disorders. Progressive supranuclear palsy (PSP) is a rare atypical Parkinsonism in the midbrain region, leading to more severe motor symptoms and very rapid pathological progression. Increased 4R tau isoform in an affected brain region of the primary 4R tauopathy is a distinct pathological character in PSP patients. In this study, GV1001 down-regulated the protein level of 4R tau specifically in an annonacin-induced PSP in vitro neuronal model as well as in vivo study using 4R TauP301L-BiFC mouse model. These findings suggest a novel role of GV1001 in 4R tauopathy and support its disease-modifying potential within the context of 4R tau\u2013driven neurodegenerative models, including PSP.<\/jats:p>","DOI":"10.1038\/s41598-026-42195-7","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:06:01Z","timestamp":1772957161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GV1001 reduces pathological 4R tau and functional deficits in models relevant to progressive supranuclear palsy"],"prefix":"10.1038","volume":"16","author":[{"given":"Kyu-Beom","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Lukianenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungsu","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"key":"42195_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer, A. L. et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 16, 552\u2013563 (2017).","journal-title":"Lancet Neurol."},{"key":"42195_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2024.101753","volume":"70","author":"F DeRosier","year":"2024","unstructured":"DeRosier, F. et al. Progressive supranuclear palsy: neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies. Dis. Mon. 70, 101753 (2024).","journal-title":"Dis. Mon."},{"key":"42195_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord"},{"key":"42195_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/WCO.0000000000001163","volume":"36","author":"A Veilleux Carpentier","year":"2023","unstructured":"Veilleux Carpentier, A. & McFarland, N. R. Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment. Curr. Opin. Neurol. 36, 309\u2013316 (2023).","journal-title":"Curr. Opin. Neurol."},{"key":"42195_CR5","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","volume":"99","author":"KH Strang","year":"2019","unstructured":"Strang, K. H., Golde, T. E. & Giasson, B. I. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab. Invest. 99, 912\u2013928 (2019).","journal-title":"Lab. Invest."},{"key":"42195_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo, T., Noble, W. & Hanger, D. P. Roles of Tau protein in health and disease. Acta Neuropathol. 133, 665\u2013704 (2017).","journal-title":"Acta Neuropathol."},{"key":"42195_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00124","volume":"11","author":"RA Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves, R. A., Wijesekara, N., Fraser, P. E. & De Felice, F. G. Behavioral abnormalities in knockout and humanized Tau mice. Front. Endocrinol. 11, 124 (2020).","journal-title":"Front. Endocrinol."},{"key":"42195_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5\u201321 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"42195_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39328-1","volume":"22","author":"N Kyalu Ngoie Zola","year":"2023","unstructured":"Kyalu Ngoie Zola, N. et al. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer\u2019s disease and primary tauopathies. Nat. Commun. 22, 3706 (2023).","journal-title":"Nat. Commun."},{"key":"42195_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2174\/1567205011666141107150331","volume":"11","author":"K Cisek","year":"2014","unstructured":"Cisek, K., Cooper, G. L., Huseby, C. J. & Kuret, J. Structure and mechanism of action of tau aggregation inhibitors. Curr. Alzheimer Res. 11, 918\u2013927 (2014).","journal-title":"Curr. Alzheimer Res."},{"key":"42195_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/ana.410430617","volume":"43","author":"P Poorkaj","year":"1998","unstructured":"Poorkaj, P. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815\u201325 (1998).","journal-title":"Ann. Neurol."},{"key":"42195_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315383","volume":"23","author":"A Corsi","year":"2022","unstructured":"Corsi, A., Bombieri, C., Valenti, M. T. & Romanelli, M. G. Tau isoforms: gaining insight into MAPT alternative splicing. Int. J. Mol. Sci. 23, 15383 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"42195_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","volume":"17","author":"M Stamelou","year":"2021","unstructured":"Stamelou, M. et al. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nat. Rev. Neurol. 17, 601\u2013620 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"42195_CR14","doi-asserted-by":"crossref","unstructured":"van Balken, I. & Litvan, I. Current and future therapeutic approaches in progressive supranuclear palsy. In Handb. Clin. Neurol. Vol. 89 493\u2013508 (2008).","DOI":"10.1016\/S0072-9752(07)01246-8"},{"key":"42195_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1586\/erv.10.92","volume":"9","author":"VE Shaw","year":"2010","unstructured":"Shaw, V. E. et al. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev. Vaccines 9, 1007\u201316 (2010).","journal-title":"Expert Rev. Vaccines"},{"key":"42195_CR16","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1158\/1078-0432.CCR-11-0184","volume":"17","author":"JA Kyte","year":"2011","unstructured":"Kyte, J. A. et al. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin. Cancer Res. 17, 4568\u201380 (2011).","journal-title":"Clin. Cancer Res."},{"key":"42195_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3892\/ijo.2014.2496","volume":"45","author":"C Staff","year":"2014","unstructured":"Staff, C., Mozaffari, F., Fr\u00f6din, J. E., Mellstedt, H. & Liljefors, M. Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int. J. Oncol. 45, 1293\u20131303 (2014).","journal-title":"Int. J. Oncol."},{"key":"42195_CR18","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-11-1385","volume":"17","author":"PF Brunsvig","year":"2011","unstructured":"Brunsvig, P. F. et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial. Clin. Cancer Res. 17, 6847\u20136857 (2011).","journal-title":"Clin. Cancer Res."},{"key":"42195_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/bju.14233","volume":"122","author":"K Moon","year":"2018","unstructured":"Moon, K. et al. A randomised, placebo-controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. BJU Int. 122, 283\u2013292 (2018).","journal-title":"BJU Int."},{"key":"42195_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00803-w","volume":"13","author":"SH Koh","year":"2021","unstructured":"Koh, S. H. et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer\u2019s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res. Ther. 13, 66 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"42195_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuro.2016.05.022","volume":"55","author":"H Park","year":"2016","unstructured":"Park, H. et al. Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals. Neurotoxicology 55, 131\u2013141 (2016).","journal-title":"Neurotoxicology"},{"key":"42195_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.neurobiolaging.2013.12.015","volume":"35","author":"HH Park","year":"2014","unstructured":"Park, H. H. et al. Novel vaccine peptide GV1001 effectively blocks \u03b2-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiol. Aging. 35, 1255\u20131274 (2014).","journal-title":"Neurobiol. Aging"},{"key":"42195_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5853\/jos.2021.00626","volume":"23","author":"HS Kwon","year":"2021","unstructured":"Kwon, H. S. et al. Neuroprotective effects of GV1001 in animal stroke model and neural cells subject to oxygen-glucose deprivation\/reperfusion injury. J. Stroke 23, 420\u2013436 (2021).","journal-title":"J. Stroke"},{"key":"42195_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbi.2023.10.021","volume":"115","author":"H Park","year":"2024","unstructured":"Park, H. et al. GV1001 modulates neuroinflammation and improves memory and behavior through the activation of gonadotropin-releasing hormone receptors in a triple transgenic Alzheimer\u2019s disease mouse model. Brain Behav. Immun. 115, 295\u2013307 (2024).","journal-title":"Brain Behav. Immun."},{"key":"42195_CR25","first-page":"1983","volume":"16","author":"HH Park","year":"2024","unstructured":"Park, H. H. et al. GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects. Aging 16, 1983\u20132004 (2024).","journal-title":"Aging"},{"key":"42195_CR26","doi-asserted-by":"publisher","first-page":"101782","DOI":"10.1016\/j.pneurobio.2020.101782","volume":"24","author":"S Shin","year":"2020","unstructured":"Shin, S. et al. Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy. Prog Neurobiol. 24, 101782 (2020).","journal-title":"Prog Neurobiol."},{"key":"42195_CR27","doi-asserted-by":"crossref","unstructured":"Percie, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 18 (7):e3000410 (2020).","DOI":"10.1371\/journal.pbio.3000410"},{"key":"42195_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0304-3940(95)11484-E","volume":"189","author":"M Goedert","year":"1995","unstructured":"Goedert, M., Jakes, R. & Vanmechelen, E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 189, 167\u20139 (1995).","journal-title":"Neurosci. Lett."},{"key":"42195_CR29","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/brain\/awab282","volume":"145","author":"N Holland","year":"2022","unstructured":"Holland, N. et al. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. Brain 145, 340\u2013348 (2022).","journal-title":"Brain"},{"key":"42195_CR30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ibneur.2024.04.008","volume":"16","author":"E Ichikawa-Escamilla","year":"2024","unstructured":"Ichikawa-Escamilla, E., Velasco-Mart\u00ednez, R. A. & Adalid-Peralta, L. Progressive supranuclear palsy syndrome: an overview. IBRO Neurosci. Rep. 16, 598\u2013608 (2024).","journal-title":"IBRO Neurosci. Rep."},{"key":"42195_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.neuron.2015.01.025","volume":"85","author":"N Menkes-Caspi","year":"2015","unstructured":"Menkes-Caspi, N. et al. Pathological tau disrupts ongoing network activity. Neuron 85, 959\u201366 (2015).","journal-title":"Neuron"},{"key":"42195_CR32","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jalz.2017.04.002","volume":"13","author":"S Kaniyappan","year":"2017","unstructured":"Kaniyappan, S., Chandupatla, R. R., Mandelkow, E. M. & Mandelkow, E. Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability. Alzheimers Dement. 13, 1270\u20131291 (2017).","journal-title":"Alzheimers Dement."},{"key":"42195_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2006.07.007","volume":"180","author":"S Lund","year":"2006","unstructured":"Lund, S. et al. The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J. Neuroimmunol. 180, 71\u201387 (2006).","journal-title":"J. Neuroimmunol."},{"key":"42195_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03237-8","volume":"5","author":"X Taylor","year":"2022","unstructured":"Taylor, X. et al. Activated endothelial cells induce a distinct type of astrocytic reactivity. Commun. Biol. 5, 282 (2022).","journal-title":"Commun. Biol."},{"key":"42195_CR35","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/brain\/awl347","volume":"130","author":"A Lannuzel","year":"2007","unstructured":"Lannuzel, A. et al. Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain 130, 816\u2013827 (2007).","journal-title":"Brain"},{"key":"42195_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.15252\/emmm.201606664","volume":"9","author":"J Bruch","year":"2017","unstructured":"Bruch, J. et al. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol. Med. 9, 371\u2013384 (2017).","journal-title":"EMBO Mol. Med."},{"key":"42195_CR37","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1523\/JNEUROSCI.1644-07.2007","volume":"27","author":"M Escobar-Khondiker","year":"2007","unstructured":"Escobar-Khondiker, M. et al. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J. Neurosci. 27, 7827\u20137837 (2007).","journal-title":"J. Neurosci."},{"key":"42195_CR38","doi-asserted-by":"publisher","first-page":"8758","DOI":"10.1002\/alz.14330","volume":"20","author":"RG Gatto","year":"2024","unstructured":"Gatto, R. G. et al. Microscopy assessment of a fluorescence [18F] flortaucipir analog (T726) shows neuropathological overlap with 3R and 4R tau lesions. Alzheimers. Dement. 20, 8758\u20138768 (2024).","journal-title":"Alzheimers. Dement."},{"key":"42195_CR39","doi-asserted-by":"crossref","unstructured":"Huhe, H. et al. Marmosets as model systems for the study of Alzheimer\u2019s disease and related dementias: substantiation of physiological tau 3R and 4R isoform expression and phosphorylation. Alzheimers Dement 21, e14366 (2025)19 (2024).","DOI":"10.1002\/alz.14366"},{"key":"42195_CR40","doi-asserted-by":"publisher","first-page":"e13069","DOI":"10.1111\/bpa.13069","volume":"32","author":"H Miyahara","year":"2022","unstructured":"Miyahara, H. et al. Independent distribution between tauopathy secondary to subacute sclerotic panencephalitis and measles virus: an immunohistochemical analysis in autopsy cases including cases treated with aggressive antiviral therapies. Brain Pathol. 32, e13069 (2022).","journal-title":"Brain Pathol."},{"key":"42195_CR41","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.3390\/cells12242776","volume":"12","author":"J Strobel","year":"2023","unstructured":"Strobel, J. et al. New perspectives in radiological and radiopharmaceutical hybrid imaging in progressive supranuclear palsy: a systematic review. Cells 12, 2776 (2023).","journal-title":"Cells"},{"issue":"1","key":"42195_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert, L. et al. Tau PET imaging: present and future directions. Mol. Neurodegener. 1219. (2017).","journal-title":"Mol. Neurodegener."},{"key":"42195_CR43","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/mdc3.13885","volume":"10","author":"AM Mena","year":"2023","unstructured":"Mena, A. M. et al. Tau in atypical Parkinsonisms: a meta-analysis of in vivo PET imaging findings. Movement Disorders Clinical Practice 10, 1725\u20131737 (2023).","journal-title":"Movement Disorders Clinical Practice"},{"key":"42195_CR44","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/mds.29924","volume":"39","author":"M Malpetti","year":"2024","unstructured":"Malpetti, M. et al. Neuroinflammation parallels 18F-PI-2620 positron emission tomography patterns in primary 4-repeat tauopathies. Mov. Disord. 39, 1480\u20131492 (2024).","journal-title":"Mov. Disord."},{"key":"42195_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.apsb.2020.08.006","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharm. Sin B. 11, 373\u2013393 (2021).","journal-title":"Acta Pharm. Sin B"},{"key":"42195_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29174212","volume":"29","author":"S Salerno","year":"2024","unstructured":"Salerno, S. et al. TSPO radioligands for neuroinflammation: an overview. Molecules 29, 4212 (2024).","journal-title":"Molecules"},{"key":"42195_CR47","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/mds.28395","volume":"36","author":"C Palleis","year":"2021","unstructured":"Palleis, C. et al. In vivo assessment of neuroinflammation in 4-repeat tauopathies. Mov. Disord. 36, 883\u2013894 (2021).","journal-title":"Mov. Disord."},{"key":"42195_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12100944","volume":"12","author":"AR Roda","year":"2020","unstructured":"Roda, A. R., Esquerda-Canals, G., Mart\u00ed-Cl\u00faa, J. & Villegas, S. Cognitive impairment in the 3xTg-AD mouse model of Alzheimer\u2019s disease is affected by A\u03b2-immunotherapy and cognitive stimulation. Pharmaceutics 12, 944 (2020).","journal-title":"Pharmaceutics"},{"key":"42195_CR49","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1440-1789.2006.00669.x","volume":"26","author":"K Arima","year":"2006","unstructured":"Arima, K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 26, 475\u2013483 (2006).","journal-title":"Neuropathology"},{"key":"42195_CR50","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Structure-based classification of tauopathies. Nature 598, 359\u2013363 (2021).","journal-title":"Nature"},{"key":"42195_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00096","volume":"12","author":"GG Kovacs","year":"2020","unstructured":"Kovacs, G. G. Astroglia and tau: new perspectives. Front. Aging Neurosci. 12, 96 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"42195_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs, G. G. et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 140, 99\u2013119 (2020).","journal-title":"Acta Neuropathol."},{"key":"42195_CR53","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/neup.12143","volume":"34","author":"M Yoshida","year":"2014","unstructured":"Yoshida, M. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 34, 555\u2013570 (2014).","journal-title":"Neuropathology"},{"key":"42195_CR54","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Interaction between A\u03b2 and Tau in the pathogenesis of Alzheimer\u2019s disease. Int. J. Biol. Sci. 17, 2181\u20132192 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"42195_CR55","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche, M. A. & Hyman, B. T. Synergy between amyloid-\u03b2 and Tau in Alzheimer\u2019s disease. Nat. Neurosci. 23, 1183\u20131193 (2020).","journal-title":"Nat. Neurosci."},{"key":"42195_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","volume":"61","author":"GK Wilcock","year":"2018","unstructured":"Wilcock, G. K. et al. Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial. J. Alzheimers Dis. 61, 435\u2013457 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"42195_CR57","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier, S. et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873\u20132884 (2016).","journal-title":"Lancet"},{"key":"42195_CR58","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s12276-023-00959-5","volume":"55","author":"S Lim","year":"2023","unstructured":"Lim, S. et al. Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in TauP301L-BiFC mice. Exp. Mol. Med. 55, 612\u2013627 (2023).","journal-title":"Exp. Mol. Med."},{"key":"42195_CR59","doi-asserted-by":"publisher","first-page":"e202302916","DOI":"10.1002\/chem.202302916","volume":"30","author":"H Lee","year":"2024","unstructured":"Lee, H. Fluorescent phenotyping of blood cells using a differential sensing strategy: differentiating physiological aging stages and neuro-degenerative disease drugs. Chemistry 30, e202302916 (2024).","journal-title":"Chemistry"},{"key":"42195_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2009.08.004","volume":"220","author":"M H\u00f6llerhage","year":"2009","unstructured":"H\u00f6llerhage, M. et al. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp. Neurol. 220, 133\u2013142 (2009).","journal-title":"Exp. Neurol."},{"key":"42195_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113070","volume":"9","author":"J Bruch","year":"2014","unstructured":"Bruch, J., Xu, H., De Andrade, A. & H\u00f6glinger, G. Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation. PLoS One 9, e113070 (2014).","journal-title":"PLoS One"},{"key":"42195_CR62","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/31508","volume":"393","author":"M Hutton","year":"1998","unstructured":"Hutton, M. et al. Association of missense and 5\u2019-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702\u2013705 (1998).","journal-title":"Nature"},{"key":"42195_CR63","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.1073\/pnas.96.14.8229","volume":"96","author":"L Varani","year":"1999","unstructured":"Varani, L. et al. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc. Natl. Acad. Sci. U.S.A. 96, 8229\u201334 (1999).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"42195_CR64","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1046\/j.1471-4159.2003.01879.x","volume":"86","author":"C Andorfer","year":"2003","unstructured":"Andorfer, C. et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582\u201390 (2003).","journal-title":"J. Neurochem."},{"key":"42195_CR65","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.neurobiolaging.2003.04.007","volume":"24","author":"EM Mandelkow","year":"2003","unstructured":"Mandelkow, E. M., Stamer, K., Vogel, R., Thies, E. & Mandelkow, E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging. 24, 1079\u20131085 (2003).","journal-title":"Neurobiol. Aging"},{"key":"42195_CR66","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3","volume":"49","author":"V Zhukareva","year":"2001","unstructured":"Zhukareva, V. et al. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann. Neurol. 49, 165\u201375 (2001).","journal-title":"Ann. Neurol."},{"key":"42195_CR67","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00401-007-0280-z","volume":"114","author":"M Ingelsson","year":"2007","unstructured":"Ingelsson, M. et al. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol. 114, 471\u20139 (2007).","journal-title":"Acta Neuropathol."},{"key":"42195_CR68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jneumeth.2009.02.015","volume":"180","author":"C Luk","year":"2009","unstructured":"Luk, C., Giovannoni, G., Williams, D. R., Lees, A. J. & de Silva, R. Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies. J. Neurosci. Methods 180, 34\u201342 (2009).","journal-title":"J. Neurosci. Methods"},{"key":"42195_CR69","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.neuron.2016.04.042","volume":"90","author":"KM Schoch","year":"2016","unstructured":"Schoch, K. M. et al. Increased 4R-Tau induces pathological changes in a human-tau mouse model. Neuron 90, 941\u20137 (2016).","journal-title":"Neuron"},{"key":"42195_CR70","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cub.2012.02.005","volume":"22","author":"Q Cai","year":"2012","unstructured":"Cai, Q., Zakaria, H. M., Simone, A. & Sheng, Z. H. Spatial parkin translocation and degradation of damaged mitochondria via mitophagy in live cortical neurons. Curr. Biol. 22, 545\u201352 (2012).","journal-title":"Curr. Biol."},{"key":"42195_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.654785","volume":"15","author":"D Yang","year":"2021","unstructured":"Yang, D. et al. Mitochondrial dynamics: a key role in neurodegeneration and a potential target for neurodegenerative disease. Front. Neurosci. 15, 654785 (2021).","journal-title":"Front. Neurosci."},{"key":"42195_CR72","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1126\/science.1152993","volume":"319","author":"R Dixit","year":"2008","unstructured":"Dixit, R., Ross, J. L., Goldman, Y. E. & Holzbaur, E. L. Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086\u20131089 (2008).","journal-title":"Science"},{"key":"42195_CR73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.pneurobio.2012.03.006","volume":"99","author":"LS Goldstein","year":"2012","unstructured":"Goldstein, L. S. Axonal transport and neurodegenerative disease: can we see the elephant?. Prog. Neurobiol. 99, 186\u201390 (2012).","journal-title":"Prog. Neurobiol."},{"key":"42195_CR74","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.neurobiolaging.2011.06.006","volume":"33","author":"NM Kanaan","year":"2012","unstructured":"Kanaan, N. M. et al. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol. Aging 33, 826 (2012).","journal-title":"Neurobiol. Aging"},{"key":"42195_CR75","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1523\/JNEUROSCI.2305-16.2016","volume":"37","author":"V Lacovich","year":"2017","unstructured":"Lacovich, V. et al. Tau isoforms imbalance impairs the axonal transport of the amyloid precursor protein in human neurons. J. Neurosci. 37, 58\u201369 (2017).","journal-title":"J. Neurosci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42195-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:35:06Z","timestamp":1781638506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42195-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42195"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42195-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Declaration of Competing Interest. The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: SJK holds equity in GemVax&KAEL Co., Ltd. and KBJ, MHL, and HJC are employee of GemVax. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8638"}}